Mathew et al. (11) found that 2/3 of COVID-19 patients displayed pronounced B cell response characterized by a relative increase in IgD-CD27- B cells and CD27+CD38+ plasmablasts, which correlated with lower T cell count and increase in inflammation markers, and similar finding were reported in other studies (38). The gene discussed is CD38; the disease is COVID-19.